Natera (NASDAQ:NTRA) CFO Sells $464,594.94 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,863 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.38, for a total value of $464,594.94. Following the transaction, the chief financial officer owned 52,432 shares in the company, valued at approximately $13,075,492.16. This trade represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The shares were sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $203,703.18.
• On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The stock was sold at an average price of $210.49, for a total value of $101,456.18.
• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $64,528.08.

Natera Stock Performance

Shares of NTRA stock opened at $267.76 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The firm has a market capitalization of $38.35 billion, a price-to-earnings ratio of -164.27 and a beta of 1.51. The stock’s 50-day simple moving average is $246.77 and its 200-day simple moving average is $222.22.

Wall Street Analyst Weigh In

A number of research firms recently commented on NTRA. Canaccord Genuity Group lifted their target price on shares of Natera from $285.00 to $330.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. upped their price target on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Morgan Stanley raised their price target on shares of Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Barclays lowered their price objective on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Finally, UBS Group set a $260.00 price objective on shares of Natera in a report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $267.83.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management acquired a new position in Natera in the 4th quarter worth approximately $29,000. Elevation Wealth Partners LLC purchased a new position in Natera during the 2nd quarter worth approximately $30,000. Palladiem LLC purchased a new position in Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC acquired a new stake in Natera during the 3rd quarter valued at approximately $32,000. Finally, International Assets Investment Management LLC lifted its stake in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.